Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg reiterates 'buy' rating on Warpaint London

(Sharecast News) - Analysts at Berenberg reiterated their 'buy' rating and 700.0p target price on makeup business Warpaint London on Wednesday, stating it was confident in the group's outlook despite Q1 turbulence. Berenberg said Warpaint's growth prospects were not diminished by volatility across Q125, in its view, noting that while growth decelerated post-January, Q1 growth of 7% year-on-year reflected an acceleration versus Q424 and highlighted resilience against an uncertain macro backdrop.

The German bank said it was encouraged by Warpaint's major store estate expansion announcements, which it expects to underwrite "a significant component" of the 15% like-for-like/pre-acquisition revenue growth that consensus estimates have in place for FY25.

"We continue to think there is potential for further growth meaningfully ahead of Warpaint's underlying end-markets and do not view the deceleration of H2 2024 growth as deserving of the de-rating that the market has delivered," said Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.